Eisai’s Alzheimer’s drug LEQEMBI could spread faster than many expect as earlier testing finds more patients and at-home dosing makes treatment simpler. But the story comes with big “what ifs,” including pressure to cut drug prices, heavy reliance on a few products, and tougher competition from larger rivals.Read more
Eisai’s Alzheimer’s drug faces growing pressure as governments push harder to cut medicine prices and competitors close in, leaving the company unusually exposed if even one key product stumbles. At the same time, faster uptake, easier testing, and new ways to deliver and expand the drug could keep growth going longer than skeptics expect.Read more
Eisai could benefit as simpler testing and clearer treatment pathways make it easier for more people with memory loss to get diagnosed and start its Alzheimer’s medicine. But the story hinges on that drug staying trusted, covered by insurers, and protected from price cuts and tougher competition.Read more
Eisai Co., Ltd. engages in the research, development, manufacture, and sale of pharmaceuticals in Japan. The company operates through pharmaceuticals business and other business segments. It offers Lenvima, a multi-kinase inhibitor which is involved in tumor angiogenesis or tumor malignancy; LEQEMBI, a humanized IgG1 monoclonal antibody against amyloid-beta (Aß) protofibrils; and Dayvigo, a novel small molecule compound. The company also provides prescription drugs; and over-the-counter drugs, as well as focuses on neurology and oncology, and other therapeutic areas. It operates in Europe, the Middle East, Africa, Russia, Oceania, the Americas, China, East Asia, the Global South, and internationally. The company was formerly known as Nihon Eisai Co., Ltd. and changed its name to Eisai Co., Ltd. in 1955. Eisai Co., Ltd. was incorporated in 1941 and is headquartered in Tokyo, Japan.
